ACT-1004-1239: testing one receptor target in progressive MS
Published by MyelinWatch:
ACT-1004-1239 · Researchers are testing a drug that blocks the receptor called CXCR7 or ACKR3 in progressive MS. MRI, nerve-response and biochemical measures will look for possible repair signals.
What is the approach?
ACT-1004-1239 blocks the chemokine receptor CXCR7, also called ACKR3: these are two names for the same target. Experimental work suggests this may alter immune-cell movement into the nervous system and support myelin-producing cells; whether either effect benefits people with progressive MS remains under study.
Approach source: Idorsia researchers — original experimental ACT-1004-1239 paper ↗
What is being studied
Researchers are testing a drug that blocks the receptor called CXCR7 or ACKR3 in progressive MS. MRI, nerve-response and biochemical measures will look for possible repair signals.
Research stage
Testing whether it helps patients
The current listing is open to participants.
What we know so far
This Phase 2 study was accepting participants in the Netherlands at country level in the official CTIS check on 25 October 2026. Greece was not listed. Its planned measures are not results, and no benefit has been established.
What this means for patients today
It is a study, not an available treatment. Country-level recruitment in the Netherlands does not establish a place at an individual centre; participation depends on the study's criteria.
- Treatment or approach
- Drug acting on the receptor CXCR7 (also called ACKR3) • progressive MS
- How it is intended to work
- Blocks the cell-surface receptor CXCR7, also called ACKR3
- Where the study is running
- The Netherlands is listed as accepting participants at country level; Greece is not listed
- Published by MyelinWatch
- Last substantive MyelinWatch update